Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoCancerVac in Mesothelioma
NCT02395679Phase 1Unknown
- Sponsor
- Erasmus MC
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MesoCancerVac in malignant pleural mesothelioma (MPM), sponsored by Erasmus MC. Primary endpoint: Dose-Limiting Toxicities at 8 weeks. Status: unknown.
02
Drugs
MesoCancerVac
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02395679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395679.